Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CRD3874 |
Synonyms | |
Therapy Description |
CRD3874 acts as a STING agonist, potentially resulting in increased type 1 interferon response and inhibition of tumor tumor growth (Cancer Res (2024) 84 (6_Supplement): 7481). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CRD3874 | CRD 3874|CRD-3874|CRD3874SI|CRD3874-SI | STING1 Agonist 19 | CRD3874 acts as a STING agonist, potentially resulting in increased type 1 interferon response and inhibition of tumor tumor growth (Cancer Res (2024) 84 (6_Supplement): 7481). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |
NCT06626633 | Phase I | CRD3874 | 2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML | Recruiting | USA | 0 |